Saturn V Capital Management LP 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Saturn V Capital Management LP disclosed 23 US equity positions worth $697.5m in its Q2 2026 13F filing. The largest position was AMLX at 11.9% of the reported book, followed by ALMS and ABVX. Against the Q1 2026 filing, it opened 3 new positions, added to 12 and reduced 6 among the top 23 holdings.
What did Saturn V Capital Management LP own in Q2 2026? Top 23 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 11.9% | $83.0m | 4,624,101 | 6% | added |
| 2 | ALMS ALUMIS INC | Healthcare | 11.8% | $82.0m | 2,915,443 | -9% | reduced |
| 3 | ABVX ABIVAX SA | Healthcare | 9.9% | $69.1m | 518,865 | -4% | reduced |
| 4 | PCVX VAXCYTE INC | Healthcare | 7.1% | $49.6m | 852,914 | 3% | added |
| 5 | IMMX IMMIX BIOPHARMA INC | 6.9% | $48.0m | 4,658,429 | 26% | added | |
| 6 | PHVS PHARVARIS N V | Healthcare | 6.5% | $45.4m | 1,314,122 | 9% | added |
| 7 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 5.6% | $38.8m | 160,938 | -1% | reduced |
| 8 | CELC CELCUITY INC | Healthcare | 5.6% | $38.7m | 370,318 | 31% | added |
| 9 | IRON DISC MEDICINE INC | Healthcare | 5.5% | $38.4m | 524,730 | 17% | added |
| 10 | CADL CANDEL THERAPEUTICS INC | 4.9% | $34.0m | 3,303,686 | 14% | added | |
| 11 | XFOR X4 PHARMACEUTICALS INC | 4.7% | $32.6m | 6,973,343 | 8% | added | |
| 12 | MNPR MONOPAR THERAPEUTICS INC | 4.1% | $28.9m | 311,976 | -10% | reduced | |
| 13 | DYN DYNE THERAPEUTICS INC | Healthcare | 3.4% | $23.5m | 1,057,493 | 9% | added |
| 14 | TRVI TREVI THERAPEUTICS INC | Healthcare | 2.8% | $19.6m | 1,052,043 | – | new |
| 15 | ZURA ZURA BIO LTD | Healthcare | 1.8% | $12.4m | 2,101,119 | 184% | added |
| 16 | SGMT SAGIMET BIOSCIENCES INC | Healthcare | 1.6% | $11.4m | 1,479,918 | – | new |
| 17 | OCULIS HOLDING AG | 1.4% | $9.5m | 684,880 | 33% | added | |
| 18 | IKT INHIBIKASE THERAPEUTICS INC | 1.1% | $7.9m | 3,869,056 | 0% | held | |
| 19 | VIR VIR BIOTECHNOLOGY INC | Healthcare | 1.1% | $7.9m | 770,643 | – | new |
| 20 | IVVD INVIVYD INC | Healthcare | 1.0% | $7.3m | 8,392,288 | -23% | reduced |
| 21 | ANRO ALTO NEUROSCIENCE INC | Healthcare | 0.7% | $4.8m | 182,829 | 105% | added |
| 22 | MSLE SATELLOS BIOSCIENCE INC | 0.4% | $2.7m | 350,000 | 0% | held | |
| 23 | OVID OVID THERAPEUTICS INC | Healthcare | 0.3% | $1.8m | 663,060 | -84% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.